Propofol, Triglycerides, and Acute Pancreatitis: A Multicenter Epidemiologic Analysis

<b>Rationale:</b> Propofol is one of the first-line sedative-hypnotic agents for critically ill adults requiring mechanical ventilation. Although propofol can elevate triglyceride levels, and the latter is a risk factor for pancreatitis, the association between propofol and acute pancreatitis is unclear. <b>Objectives:</b> We sought to determine the clinical impact and potential associations between propofol infusion, hypertriglyceridemia, and acute pancreatitis. <b>Methods:</b> This is an observational multicenter study of adults (⩾18 yr old) who were admitted to an intensive care unit, who required mechanical ventilation and received continuous propofol infusion for at least 24 hours. The primary outcomes were the frequency of hypertriglyceridemia (>400 mg/dl) and acute pancreatitis. Further analyses were done to determine the clinical impact of elevated triglyceride levels (i.e., sedation changes) and risk factors for pancreatitis development. <b>Results:</b> Of 11,828 patients included, 33.2% (<i>n</i> = 3,922) had triglyceride levels measured, of whom 21.7% (<i>n</i> = 851) had hypertriglyceridemia at 4.5 days (SD = 6.8) after propofol initiation. Of those still requiring sedation, 70.4% (<i>n</i> = 576/818) received alternative sedatives after developing hypertriglyceridemia. Pancreatitis occurred in 1.2% of patients (<i>n</i> = 47/3,922) and was more frequent in those with hypertriglyceridemia (3.2%, 27/851; vs. 0.7%, 20/3,071; <i>P</i> < 0.001). After adjustment for potential confounding variables, each 100 mg/dl increase in triglyceride levels was associated with an 11% increase in risk of pancreatitis. Propofol dose was not associated with pancreatitis development. <b>Conclusions:</b> Acute pancreatitis is uncommon in patients receiving propofol infusion, and it occurs over a wide range of triglyceride levels, indicating a multifactorial pathophysiology. Hypertriglyceridemia frequently prompts the use of alternative sedatives. Further study is needed to determine how to best monitor and treat hypertriglyceridemia in critically ill patients receiving propofol infusion.

Authors

Institutions

Publication Details

Journal
Annals of the American Thoracic Society
Published
2024-10-11
DOI
https://doi.org/10.1513/annalsats.202407-781oc
Citations
10
Primary Topic
Intensive Care Unit Cognitive Disorders
Type
article
Field-Weighted Citation Impact
4.22

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Propofol, Triglycerides, and Acute Pancreatitis: A Multicenter Epidemiologic Analysis

Jiawen Deng, Fangwen Zhou, Keshav Poudel, Hemang Yadav et al.
10 citations
Annals of the American Thoracic Society
Intensive Care Unit Cognitive Disorders
4.22
article

Propofol, Triglycerides, and Acute Pancreatitis: A Multicenter Epidemiologic Analysis

Jiawen Deng, Fangwen Zhou, Keshav Poudel, Hemang Yadav, Caitlin S. Brown, Kiyan Heybati, Ognjen Gajic, Zeeshan Rizwan, Guozhen Xie, Christopher T Acker
article en
10 citations

Abstract

<b>Rationale:</b> Propofol is one of the first-line sedative-hypnotic agents for critically ill adults requiring mechanical ventilation. Although propofol can elevate triglyceride levels, and the latter is a risk factor for pancreatitis, the association between propofol and acute pancreatitis is unclear. <b>Objectives:</b> We sought to determine the clinical impact and potential associations between propofol infusion, hypertriglyceridemia, and acute pancreatitis. <b>Methods:</b> This is an observational multicenter study of adults (⩾18 yr old) who were admitted to an intensive care unit, who required mechanical ventilation and received continuous propofol infusion for at least 24 hours. The primary outcomes were the frequency of hypertriglyceridemia (>400 mg/dl) and acute pancreatitis. Further analyses were done to determine the clinical impact of elevated triglyceride levels (i.e., sedation changes) and risk factors for pancreatitis development. <b>Results:</b> Of 11,828 patients included, 33.2% (<i>n</i> = 3,922) had triglyceride levels measured, of whom 21.7% (<i>n</i> = 851) had hypertriglyceridemia at 4.5 days (SD = 6.8) after propofol initiation. Of those still requiring sedation, 70.4% (<i>n</i> = 576/818) received alternative sedatives after developing hypertriglyceridemia. Pancreatitis occurred in 1.2% of patients (<i>n</i> = 47/3,922) and was more frequent in those with hypertriglyceridemia (3.2%, 27/851; vs. 0.7%, 20/3,071; <i>P</i> < 0.001). After adjustment for potential confounding variables, each 100 mg/dl increase in triglyceride levels was associated with an 11% increase in risk of pancreatitis. Propofol dose was not associated with pancreatitis development. <b>Conclusions:</b> Acute pancreatitis is uncommon in patients receiving propofol infusion, and it occurs over a wide range of triglyceride levels, indicating a multifactorial pathophysiology. Hypertriglyceridemia frequently prompts the use of alternative sedatives. Further study is needed to determine how to best monitor and treat hypertriglyceridemia in critically ill patients receiving propofol infusion.

Annals of the American Thoracic SocietyVol. 22(2)
Mayo Clinic (US), University of Toronto (CA), Mayo Clinic in Florida (US), Pulmonary and Critical Care Associates (US), McMaster University (CA)
National Heart, Lung, and Blood Institute
Good health and well-being
Openalex Percentile: Top 5%
Intensive Care Unit Cognitive Disorders
4.22
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.